Results 131 to 140 of about 202,953 (268)

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Metabolic Imaging and Molecular Signatures Reveal Metabolic Phenotypes in Recurrent Glioblastoma. [PDF]

J Nucl Med
Li EJ, Kraya A, Costa-Pinheiro P, Scheuermann J, Young AJ, Schubert E, Aboian M, Doot R, Ware JB, Pantel AR, Binder ZA, Storm PB, Resnick AC, Amankulor NM, O'Rourke DM, Desai A, Nasrallah MP, Brem S, Bagley SJ, Mankoff D, Nabavizadeh A.   +20 more
europepmc   +1 more source

Nonviral Gold Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Ribonucleoprotein and Long DNA Transgenes Into Primary Blood Cells

Advanced NanoBiomed Research, EarlyView.
CRISPR/Cas9 has revolutionized the field of gene therapy, but delivery remains an outstanding issue. We propose a nonviral gold‐nanoparticle platform for co‐delivery of CRISPR/Cas9 ribonucleoprotein and long 2.1 kilobase dsDNA transgene constructs. This CRISPR‐AuNP is inexpensive to produce and mediate gene editing and DNA delivery in T cells and CD34+
Rachel A. Cunningham, Karthikeya S. V. Gottimukkala, Daniel D. Lane, Katrina Poljakov, Patricia Lipson, Mark R. Enstrom, Alessandro Rizzi, Aude G. Chapuis, Jennifer E. Adair   +8 more
wiley   +1 more source

The Role of ACE I/D Polymorphism in Glioblastoma Pathogenesis: A Study on the Turkish Population. [PDF]

In Vivo
Türk O, Güvenç Y, Yilmaz SG, Yaltirik CK, Demirel N, Dağçinar A, Çakir OA, Şanlier N, Toprak UE, Kurt MT, Isbir T.   +10 more
europepmc   +1 more source

Epstein-Barr Virus in Brain Cancer-Friend or Foe? [PDF]

Int J Mol Sci
Brzozowski M, Góralczyk M, Bogacki S, Polz-Dacewicz M.   +3 more
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Pharmacological Ascorbate Restrains Epithelial-Mesenchymal Transition and Invasion in Glioblastoma Cells via Extracellular H₂O₂ Generation. [PDF]

Int J Mol Sci
Wattanathamsan O, Chantaravisoot N, Bootsri R, Kalpongnukul N, Youngsanbhu N, Oliva CR, Griguer CE, Buranasudja V.   +7 more
europepmc   +1 more source

The multiforme of glioblastoma [PDF]

Neuro-Oncology, 2018
Farshad, Nassiri, Kenneth, Aldape, Gelareh, Zadeh   +2 more
openaire   +2 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source